Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
|
10.01.03 |
Drugs which suppress the rheumatic disease process |
|
|
10.01.03 |
Drugs affecting the immune response |
|
|
Baricitinib (Olumiant®) (tablet)
|
Formulary
|
Moderate - severe atopic dermatitis which has not responded to dupilumab, or in those who qualify for, but are unsuitable for, dupilumab. MEC/DPC: not supported other than in exceptional circumstances (use IFR process for eligible patients)
|
10.01.03 |
Cytokine modulators |
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Traffic Light Status Information
Status |
Description |

|
Suitable for prescribing by all in both primary and secondary care. |

|
Specialist recommended but suitable for continuation in primary care. |

|
Specialist initiated but suitable for continuation in primary care. |

|
Specialist initiated and for continuation in primary care under a locally approved shared care guideline. |

|
Suitable for prescribing in specialist settings (secondary care) only. |

|
Secondary care medicines to be used under specialised commissioning arrangements only. |

|
For primary care, either via FP10 or supplied through specialist services. These products may be stocked by hospital
pharmacies only for supply to primary care units/wards or for continuing supplies for patients admitted on therapy. |

|
Not recommended for use. |
|
|